Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pharmacokinetics and Safety of ABBV-722 with Itraconazole in Healthy Adults
NCT07599761Phase 1Completed
- Sponsor
- AbbVie Inc.
- Start
- May 2026
- Primary completion
- Sep 2026
- Modality
- Antibody Conjugates, Monoclonal Antibodies, Engineered Antibody Formats
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of ABBV-722, sponsored by AbbVie Inc. Primary endpoints: Maximum Observed Plasma Concentration at Day 14, Time to Maximum Observed Plasma Concentration at Day 14 and 5 more. Started May 2026; status: completed.
02
Drugs
ABBV-722
Beyond the preview
Go deeper on NCT07599761.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07599761.